Strong Buy Case for Abbott Laboratories (ABT)

Alpha Wealth Funds, LLC released its Q2 2026 letter for the Insiders Fund, detailing their performance and investment decisions. The fund suffered a 1.45% loss in June, but outperformed the S&P 500's 0.95% decline during the same period. Abbott Laboratories (NYSE:ABT) was highlighted as a key holding, with a 10.52% one-month return.

The company, founded in 1888, operates in four segments: Diagnostics, Medical Devices, Established Pharmaceuticals, and Nutrition. Abbott Laboratories is known for its Dividend King status, having increased its dividend for over 50 consecutive years. The fund's insiders made significant purchases, including John G. Stratton and Daniel J. Starks.

Despite Abbott Laboratories' strong performance, the fund's broader strategy favors certain AI stocks with greater upside potential and less downside risk.